Study finds connection between quantum theory, information theoryBNP Paribas Financial Markets lifted its holdings in shares of Glaukos Co. ( NYSE:GKOS – Free Report ) by 186.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,726 shares of the medical instruments supplier’s stock after acquiring an additional 8,942 shares during the quarter. BNP Paribas Financial Markets’ holdings in Glaukos were worth $1,788,000 as of its most recent filing with the Securities and Exchange Commission. A number of other institutional investors have also recently added to or reduced their stakes in GKOS. EFG Asset Management North America Corp. lifted its stake in shares of Glaukos by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock worth $3,216,000 after purchasing an additional 128 shares in the last quarter. Values First Advisors Inc. acquired a new position in Glaukos during the 3rd quarter worth approximately $25,000. New York State Teachers Retirement System boosted its holdings in Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock worth $6,272,000 after acquiring an additional 200 shares during the period. KBC Group NV grew its position in Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. Finally, Inspire Investing LLC raised its stake in shares of Glaukos by 6.9% during the third quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 206 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors. Insider Activity In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink . Also, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here . Corporate insiders own 6.40% of the company’s stock. Glaukos Stock Performance Glaukos ( NYSE:GKOS – Get Free Report ) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.50) EPS. Equities research analysts forecast that Glaukos Co. will post -1.89 EPS for the current year. Wall Street Analyst Weigh In GKOS has been the subject of several analyst reports. Stifel Nicolaus upped their target price on shares of Glaukos from $145.00 to $153.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. UBS Group began coverage on Glaukos in a research note on Friday. They set a “buy” rating and a $182.00 target price for the company. Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research note on Monday, December 2nd. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. Finally, StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and an average price target of $140.00. Check Out Our Latest Analysis on Glaukos Glaukos Profile ( Free Report ) Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. See Also Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter .Dodgers shortstop Jose Hernandez suspended for 2025 ACL season under minor league drug program
234win 999
。
RICHARDSON, TX / ACCESSWIRE / December 19, 2024 / Optex Systems Holdings, Inc. (Nasdaq:OPXS), a leading manufacturer of precision optical sighting systems for domestic and worldwide military and commercial applications, announced financial results for the year ended September 29, 2024. Danny Schoening, CEO of Optex Systems Holdings, Inc., commented, "To build on last year's comments, this was again, another strong year for Optex. This was accomplished with multi-year wins on every major platform that we support. Laser Protected Periscopes, Laser Filter Units, Laser Interference Filters, M22 Binoculars, and other optical assemblies have filled our backlog and driven favorable factory leverage at both of our facilities. In addition, our suppliers have stepped up to the delivery challenges and we've selectively increased various internal bottlenecks to fuel the output. I would like to thank all of our employees, customers, and shareholders for their continued support in 2024 as we anticipate these trends to continue in 2025." Backlog as of September 29, 2024 was $44.2 million. This compares to a backlog of $41.8 million as of October 1, 2023, representing an increase of $2.4 million, or 5.7%. For the year ended September 29, 2024, our total revenues increased by $8.3 million, or 32.5%, compared to the prior year. The increase in revenue reflects increases at both the Optex Richardson segment of $6.1 million and the Applied Optics Center segment of $2.2 million. The increase in revenue was driven by increased customer demand for military products across both operating segments partially offset by lower customer demand in optical assemblies at the Applied Optics Center. Gross profit increased $2.9 million, or 44.0%, and the gross margin percentage increased by 2.2 points from 25.8% in the 2023 fiscal year to 28.0% in the 2024 fiscal year. Optex Systems gross profit increased by $1.4 million and the gross margin percentage increased to 20.7% as compared to 19.7% in the prior year. Applied Optics Center gross profit increased by $1.5 million and the gross margin percentage increased to 34.1% as compared to 29.3% in the prior year. The increase in each segment and consolidated gross profit is primarily attributable to higher revenue and increased absorption of fixed cost. Consolidated operating income increased by $2.0 million, or 73.0%, in the year ended September 29, 2024 to $4.8 million as compared to the prior year operating income of $2.8 million. Both operating segments realized an increase in operating income which is primarily attributable to higher revenue and gross profit, partially offset by increases in general and administrative costs. As of September 29, 2024, Optex Systems Holdings had working capital of $15.1 million, as compared to $13.5 million as of October 1, 2023. During the twelve months ended September 29, 2024, we generated operating cash of $1.8 million, primarily driven by increased revenue and net income. For the twelve months ended September 29, 2024, there was no net change against the outstanding credit facility balance of $1.0 million. At September 29, 2024, the Company had approximately $1.0 million in cash and an outstanding payable balance of $1.0 against its $3.0 million line of credit. As of September 29, 2024, our outstanding accounts receivable balance was $3.8 million, which has been collected during the first quarter of fiscal 2025. During the first quarter of 2025, we paid down our credit facility to zero. Our key performance measures for year ended September 29, 2024 and October 1, 2023 are summarized below. During the twelve months ended September 29, 2024, the Company booked $36.4 million in new orders, representing a 5.2% increase from the prior year period orders of $34.6 million. The orders for the most recently completed twelve months consist of $23.5 million for our Optex Richardson segment and $12.9 million attributable to the Applied Optics Center segment. The table below summarizes our twelve-month operating results for the periods ended September 29, 2024 and October 1, 2023, in terms of both the GAAP net income measure and the non-GAAP Adjusted EBITDA measure. We believe that including both measures allows the reader better to evaluate our overall performance. Adjusted EBITDA has limitations and should not be considered in isolation or a substitute for performance measures calculated under GAAP. This non-GAAP measure excludes certain cash expenses that we are obligated to make. In addition, other companies in our industry may calculate Adjusted EBITDA differently than we do or may not calculate it at all, which limits the usefulness of Adjusted EBITDA as a comparative measure. During the year ended September 29, 2024, we recorded net income of $3.8 million as compared to net income of $2.3 million during the year ended October 1, 2023. The increase of net income of $1.5 million is primarily attributable to increased operating income of $2.0 million, offset by increased federal income taxes of ($0.5) million. Our Adjusted EBITDA increased by $2.3 million to $5.7 million during the twelve months ended September 29, 2024 as compared to $3.4 million during the twelve months ended October 1, 2023. The increase in EBITDA is primarily driven by increased net income, offset by increased taxes, depreciation and amortization, and stock compensation. Highlights of the Consolidated and Segment Results of Operations have been prepared in accordance with GAAP. These financial highlights do not include all information and disclosures required in the consolidated financial statements and footnotes and should be read in conjunction with our Annual Report on Form 10-K for the twelve months ended September 29, 2024 filed with the SEC on December 19, 2024. Optex Systems Holdings, Inc. Consolidated Balance Sheets The accompanying notes in our Annual Report on Form 10-K for the twelve months ended September 29, 2024 filed with the SEC on December 19, 2024 are an integral part of these financial statements. Optex Systems Holdings, Inc. Consolidated Statements of Income The accompanying notes in our Annual Report on Form 10-K for the twelve months ended September 29, 2024 filed with the SEC on December 19, 2024 are an integral part of these financial statements. ABOUT OPTEX SYSTEMS Optex, which was founded in 1987, is a Richardson, Texas based ISO 9001:2015 certified concern, which manufactures optical sighting systems and assemblies, primarily for Department of Defense (DOD) applications. Its products are installed on various types of U.S. military land vehicles, such as the Abrams and Bradley fighting vehicles, Light Armored and Armored Security Vehicles, and have been selected for installation on the Stryker family of vehicles. Optex also manufactures and delivers numerous periscope configurations, rifle and surveillance sights, and night vision optical assemblies. Optex delivers its products both directly to the military services and to prime contractors. For additional information, please visit the Company's website at www.optexsys.com . Safe Harbor Statement This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the products and services described herein. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," and similar expressions. These forward-looking statements represent our expectations, beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding growth strategy; product and development programs; financial performance and financial condition (including revenue, net income, profit margins and working capital); customer demand; orders and backlog; expected timing of contract deliveries to customers and corresponding revenue recognition; increases in the cost of materials and labor; costs remaining to fulfill contracts; contract loss reserves; labor shortages; follow-on orders; supply chain challenges; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the defense industry. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs and military spending, the timing of such funding, general economic and business conditions, including unforeseen weakness in the Company's markets, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in the U.S. Government's interpretation of federal procurement rules and regulations, changes in spending due to policy changes in any new federal presidential administration, market acceptance of the Company's products, shortages in components, production delays due to performance quality issues with outsourced components, inability to fully realize the expected benefits from acquisitions and restructurings or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, changes to export regulations, increases in tax rates, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, unanticipated costs under fixed-price service and system integration engagements, changes in the market for microcap stocks regardless of growth and value and various other factors beyond our control. You must carefully consider any such statement and should understand that many factors could cause actual results to differ from the Company's forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. You should carefully evaluate such statements in light of factors described in the Company's filings with the SEC, especially on Forms 10-K, 10-Q and 8-K. In various filings the Company has identified important factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties. Contact: IR@optexsys.com 1-972-764-5718 SOURCE: Optex Systems Holdings, Inc. View the original on accesswire.comLightning ride electric power play to 4-2 victory over CanucksAadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi Bioscience
Western Michigan beats Eastern Michigan 26-18 to become bowl eligibleAlgert Global LLC Purchases New Position in Centrus Energy Corp. (NYSE:LEU)WALTHAM, Mass. , Dec. 19, 2024 /PRNewswire/ -- Veralto (NYSE: VLTO ), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital ResourcesTM , announced today that its board of directors has approved a 22% increase to its quarterly cash dividend, and accordingly approved a quarterly cash dividend of $0.11 per share of its common stock, payable on January 31, 2025 to holders of record as of the close of business on December 31, 2024 . About Veralto With annual sales of $5 billion , Veralto is a global leader in essential technology solutions with a proven track record of solving some of the most complex challenges we face as a society. Our industry-leading companies with globally recognized brands are building on a long-established legacy of innovation and customer trust to create a safer, cleaner, more vibrant future. Headquartered in Waltham, Massachusetts , our global team of 16,000 associates is committed to making an enduring positive impact on our world and united by a powerful purpose: Safeguarding the World's Most Vital ResourcesTM . SOURCE Veralto
‘MAGA Is Not My Mortal Enemy’: Prominent Left-Wing Pundit Cenk Uygur ‘Optimistic’ After Trump Win
Now is the perfect time to snap up a robot vacuum — not only will you save time and elevate your home cleaning routine, you will also get it for an unbeatable price. The Lefant M210 Pro Robot Vacuum Cleaner offers an impressive combination of powerful cleaning, advanced features, and affordability, all for $169.90 on Amazon Australia. It’s designed with a range of smart technologies and provides an effective and hassle-free cleaning experience that works for any home, especially those with pets or hard floors. Know the news with the 7NEWS app: Download today Whether you’re tackling stubborn pet hair, dust, or debris, this robot vacuum makes cleaning easier than ever. One of the best features of the Lefant M210 Pro is its versatile cleaning modes, which offer six different options to suit various cleaning needs. The Arranged Cleaning (Zig-zag Route) mode efficiently covers the entire floor with systematic cleaning paths, ensuring thorough coverage. Random Cleaning is perfect for quick, less structured cleanups, making it ideal for everyday messes. The Spot Cleaning mode targets high-traffic areas or concentrated messes, focusing on problem zones that need extra attention. Cleaning Along the Edge of the Wall is designed to clean along walls and corners, where dust and debris tend to accumulate. With the Schedule Cleaning option, users can set a cleaning schedule, allowing the vacuum to clean automatically while they’re away. Finally, the Manual Control Direction mode provides users with the flexibility to guide the robot in any direction manually, offering complete control over its movements. Users can adjust the cleaning mode and suction power directly via the Lefant Life App, making it incredibly easy to customise cleaning based on room size, mess type, and floor surface. Traditional robot vacuums often struggle with tangled hair and debris in their rotating brushes. The Lefant M210 Pro eliminates this issue with its brushless nozzle design, which not only simplifies maintenance but also improves suction efficiency. The powerful 2200Pa suction power, combined with two side brushes, ensures that hair, dust, and debris are effortlessly drawn into the large 500ml dustbin. The two layers of filtration also prevent secondary contamination, k eeping your home cleaner for longer. The M210 Pro is equipped with FreeMove 3.0 technology, which uses a built-in 6D anti-collision infrared sensor for precise navigation. The vacuum can detect obstacles in 720-degree omnidirectional angles, allowing it to avoid furniture, walls, and other barriers with ease. This innovative sensor system reduces the chances of wear and tear on the device and helps it navigate narrow spaces with precision, such as under beds and sofas. The M210 Pro can also detect stairs, preventing accidental falls, and is capable of climbing carpets for efficient cleaning across different surfaces. The Lefant M210 Pro is ideal for cleaning tight spaces under furniture and in corners. Its low-profile body ensures it can navigate underneath beds, sofas, and other low-clearance furniture, ensuring that no area is left untouched. Despite its compact size, the vacuum has a powerful motor and an impressive runtime of up to 120 minutes on a single charge, making it perfect for larger rooms or homes. For added convenience, the Lefant M210 Pro can be controlled via the Lefant Life App, which allows users to monitor cleaning paths, schedule cleanings, and adjust suction power. Shoppers on Amazon Australia’s website have given it a 4.3-star rating and are loving it. “Super simple, does the job, great for the price,” one person said. “It’s not too noisy and has a great coverage time that sweeps most of the debris around the house,” another shopper added. “Such a great vacuum,” someone else said. To purchase the vacuum, head to Amazon Australia’s website here.Strong top and bottom-line results driven by ongoing strength of the Marketing & Distribution segment Operating cash flow for full year fiscal 2024 increased by $64.2 million versus fiscal 2023 OXNARD, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (Nasdaq: AVO) (“Mission” or the “Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados with additional offerings in mangos and blueberries, today reported its financial results for the fiscal fourth quarter ended October 31, 2024. Fiscal Fourth Quarter 2024 Financial Overview: Total revenue increased 37% to $354.4 million compared to the same period last year Net income of $17.3 million, or $0.24 per diluted share, compared to $4.0 million, or $0.06 per diluted share, for the same period last year Adjusted net income of $19.6 million, or $0.28 per diluted share, compared to $7.5 million, or $0.11 per diluted share, for the same period last year Adjusted EBITDA increased 113% to $36.9 million, compared to $17.3 million in the same period last year Full Year 2024 Financial Overview Total revenue increased 29% to $1.23 billion compared to prior year, primarily driven by higher average per-unit avocado sales prices. Blueberries and mangos also contributed to growth as industry supply constraints supported a higher pricing environment Net income of $36.7 million, or $0.52 per diluted share, compared to net loss of $(2.8) million or $(0.04) per diluted share in the prior year Adjusted net income of $52.8 million, or $0.74 per diluted share, compared to $13.3 million, or $0.19 per diluted share last year Adjusted EBITDA increased 123% to $107.8 million compared to $48.4 million in the prior year driven primarily by stronger per-unit gross profit performance from the Marketing & Distribution and Blueberries segments, the latter of which correlated directly to the higher pricing environment experienced during the fiscal year Owned exportable avocado production volume decreased approximately 60% to 43 million pounds for the 2024 harvest season; volume was negatively impacted by weather-related events in the current year Cash flow from operations was $93.4 million compared to $29.2 million in the prior year CEO Message “Mission delivered a strong fourth quarter that rounded out an exceptional full year fiscal 2024 performance where we realized $1.23 billion in revenue and generated $107.8 million in adjusted EBITDA, demonstrating the strength of our business model and industry leading positioning,” stated Steve Barnard, CEO of Mission. “As previously announced, our Marketing & Distribution segment drove the strong fourth quarter performance, successfully leveraging our global sourcing network amid a sustained higher pricing environment to achieve per-unit margins exceeding our targeted range. The positive impact of our fourth quarter performance combined with our solid operational execution across the fiscal year drove a $64.2 million increase in operating cash flow versus fiscal 2023, further strengthening our capital structure and enhancing our flexibility.” Mr. Barnard continued, “Looking ahead to fiscal 2025, we will continue to focus on operational excellence, strategic growth initiatives, and sound capital allocation to drive shareholder value. While we anticipate some pricing moderation as additional supply sources become available, this environment typically supports increased consumption, and we remain well-positioned to capitalize on this growth through our unique capability to provide consistent year-round avocado supply. Beyond avocados, we are also excited about growing our mango program and expanding our presence in blueberries this year, both of which leverage our existing assets and capabilities while providing additional long-term growth opportunities.” Fiscal Fourth Quarter 2024 Consolidated Financial Review Total revenue for the fourth quarter of fiscal 2024 increased $96.5 million or 37% to $354.4 million compared to the same period last year. The increase was primarily driven by the Marketing & Distribution segment, where average per-unit avocado sales prices increased 36% on relatively flat avocado volume sold. These price and volume dynamics resulted from constrained avocado supply during the quarter due to weather impacts on fruit development and production in Peru. Despite lower Peruvian volumes, the Company effectively leveraged its diverse sourcing network across California, Colombia, and Mexico to drive a 9% increase in North American avocado sales volumes compared to the prior year. Mission’s strategic decision to prioritize the North American market, combined with strong consumer demand at higher price points and retail promotional activity contributed to the favorable pricing dynamics. Gross profit increased $28.0 million in the fourth quarter of fiscal 2024 to $55.8 million, compared to the same period last year, and gross profit percentage increased 490 basis points, to 15.7% of revenue. The increases were primarily attributed to strong per-unit margins on avocados sold in the Marketing and Distribution segment. The Blueberries segment also contributed to the increase with higher volumes while per-unit margins remained generally consistent with the prior year. Selling, general and administrative expense (“SG&A”) for the fourth quarter increased $6.6 million or 32% to $27.2 million, compared to the same period last year primarily due to higher employee related costs, including performance-based incentive compensation and stock-based compensation expense and statutory profit-sharing expense. Higher performance-based incentive compensation is largely explained by the Company’s improved operating performance for the fiscal year relative to the prior year. Net income for the fourth quarter of fiscal 2024 was $17.3 million, or $0.24 per diluted share, compared to $4.0 million, or $0.06 per diluted share, for the same period last year. Adjusted net income for the fourth quarter of fiscal 2024 was $19.6 million, or $0.28 per diluted share, compared to $7.5 million, or $0.11 per diluted share, for the same period last year. Adjusted EBITDA was $36.9 million for the fourth quarter of fiscal 2024, an increase of $19.6 million or 113% as compared to $17.3 million in the prior year period, driven primarily by stronger per-unit gross profit performance from the Marketing & Distribution and Blueberries segments. Fiscal Fourth Quarter Business Segment Performance Marketing & Distribution Net sales in the Marketing & Distribution segment increased 35% to $319.6 million for the fourth quarter, driven by avocado pricing increases as described previously. Segment adjusted EBITDA increased $14.8 million or 137% to $25.6 million, primarily due to improved per-unit gross margin on avocados sold. International Farming Total sales in the International Farming segment for the fourth quarter were $30.3 million, compared to $40.3 million for the same period last year primarily due to lower volumes of owned avocados sold, stemming from unfavorably warm weather conditions in Peru during the early stages of fruit development, partially offset by higher average sales prices that were supported by constrained industry volumes. Segment adjusted EBITDA was $2.7 million, compared to $1.1 million for the same period last year, as higher sales prices and cost savings measures more than offset the adverse impact of lower harvest yields on fixed cost absorption. Blueberries Sales in the Blueberries segment have traditionally been concentrated in the first and fourth quarters of the fiscal year in alignment with the Peruvian blueberry harvest season. Net sales in the Blueberries segment increased 62% to $31.6 million for the fourth quarter, compared to $19.5 million for the same period last year, driven by volume from new plantings and yield improvements. Yield growth was driven by improved weather patterns during the current harvest season in Peru, as cooler temperatures have been experienced since the end of El Niño conditions in May 2024. Segment adjusted EBITDA increased 59% to $8.6 million for the fourth quarter, compared to $5.4 million for the same period last year, as a result of the growth in volumes. Balance Sheet and Cash Flow Cash and cash equivalents were $58.0 million as of October 31, 2024, compared to $42.9 million as of October 31, 2023. Net cash provided by operating activities improved by $64.2 million to $93.4 million for the year ended October 31, 2024, as compared to $29.2 million last year. The growth in operating cash flow was primarily driven by improved operating performance during fiscal 2024. Further supporting the improvement in operating cash flow was favorable working capital management. While higher avocado pricing drove increases in inventory and accounts receivable, these increases were more than offset by higher grower payable balances, driven primarily by those same higher prices, and higher accounts payable and accrued expenses, the latter of which was significantly impacted by incentive compensation and statutory profit-sharing accruals in the current year. In addition, higher accounts payable and accrued expenses were attributed to the impact of higher volume and increased acreage within our Blueberries segment. Capital expenditures were $32.2 million for the year ended October 31, 2024 compared to $49.8 million last year. Capital expenditures were comprised primarily of avocado orchard development, pre-production orchard maintenance and land improvements in Guatemala; pre-production avocado orchard maintenance, blueberry land development and plant cultivation, and blueberry cooling facility construction costs in Peru; and distribution facility construction costs in the United Kingdom. During 2024, the International Farming segment also began construction of a pack house in Guatemala. Outlook For the first quarter of fiscal year 2025, the Company is providing the following industry outlooks that will drive performance: Industry volumes in the fiscal 2025 first quarter are expected to be consistent with the prior year period. While supply from Mexico has been constrained during the early part of the quarter due to fruit maturity and sizing, we expect industry volumes to ramp up as we move to the latter portion of quarter as we expect a larger Mexican harvest season. Pricing is expected to be higher on a year-over-year basis by approximately 20% compared to the $1.40 per pound average experienced in the first quarter of fiscal 2024, indicative of continued strength in demand. The blueberries harvest season in Peru will peak during the first quarter. The Company expects to see meaningful volume increases from owned farms resulting from yield improvements and new acreage in production, but the impact on revenue will likely be offset by lower average sales prices resulting from higher overall industry volumes from Peru. Pricing is expected to be approximately 30% lower compared to the first quarter of fiscal 2024, which will negatively impact segment adjusted EBITDA during the quarter as compared to the previous year when weather-related supply constraints led to abnormally high sales prices. Capital expenditures were lower than expected for fiscal 2024 by approximately $10 million due to the timing of vendor payments associated with packhouse construction in Guatemala and blueberry plant development in Peru, both of which will carryover into fiscal 2025. For fiscal 2025, total capital expenditures inclusive of the 2024 carryover are expected to be between $50 to $55 million. The spend will be allocated primarily to the International Farming and Blueberries segments. Within the International Farming segment, spend will be concentrated in Guatemala for pre-production avocado orchard maintenance and packhouse construction. Within the Blueberries segment, spend will be concentrated on land development and plant cultivation in Peru. Conference Call and Webcast As previously announced, the Company will host a conference call to discuss its fourth quarter of fiscal 2024 financial results today at 5:00 p.m. ET. The conference call can be accessed live over the phone by dialing (877) 407-9039 or for international callers by dialing (201) 689-8470. A replay of the call will be available through January 2, 2025 by dialing (844) 512-2921 or for international callers by dialing (412) 317-6671; the passcode is 13750485. The live audio webcast of the conference call will be accessible in the News & Events section on the Company's Investor Relations website at https://investors.missionproduce.com. An archived replay of the webcast will also be available shortly after the live event has concluded. Non-GAAP Financial Measures This press release contains the non-GAAP financial measures “adjusted net income” and “adjusted EBITDA.” Management believes these measures provide useful information for analyzing the underlying business results. These measures are not in accordance with, nor are they a substitute for or superior to, the comparable financial measures by generally accepted accounting principles. Adjusted net income (loss) refers to net income (loss) attributable to Mission Produce, before stock-based compensation expense, unrealized gain (loss) on derivative financial instruments, foreign currency gain (loss), farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction costs, amortization of inventory adjustments and intangible asset recognized from business combinations, further adjusted by any special, non-recurring, or one-time items such as remeasurement, impairment or discrete tax charges that are distortive to results, and tax effects of these items, if any, and the tax-effected impact of these non-GAAP adjustments attributable to noncontrolling interest, allocable to the noncontrolling owners based on their percentage of ownership interest. Adjusted EBITDA refers to net income (loss), before interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, other income (expense), and income (loss) from equity method investees, further adjusted by asset impairment and disposals, net of insurance recoveries, farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction costs, amortization of inventory adjustments recognized from business combinations, and any special, non-recurring, or one-time items such as remeasurements or impairments, and any portion of these items attributable to the noncontrolling interest. Effective for the fourth quarter of 2024, the Company made a change in presentation of its reconciliation of adjusted EBITDA to its comparable GAAP financial measure to include a subtotal of the non-GAAP adjustments before the effect of the noncontrolling interest adjustment called “adjusted EBITDA before adjustment for noncontrolling interest.” The presentation change has no impact to total adjusted EBITDA. The Company believes the addition of the subtotal within the reconciliation is useful because it better aligns with management’s sequence of review of the information in the reconciliation. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measure are provided in the table at the end of this press release. About Mission Produce, Inc. Mission Produce is a global leader in the worldwide avocado business with additional offerings in mangos and blueberries. Since 1983, Mission Produce has been sourcing, producing and distributing fresh Hass avocados, and currently services retail, wholesale and foodservice customers in over 25 countries. The vertically integrated Company owns and operates four state-of-the-art packing facilities in key growing locations globally, including California, Mexico and Peru and has additional sourcing capabilities in Chile, Colombia, the Dominican Republic, Guatemala, Brazil, Ecuador, South Africa and more, which allow the company to provide a year-round supply of premium fruit. Mission’s global distribution network includes strategically positioned forward distribution centers across key markets throughout North America, China, Europe, and the UK, offering value-added services such as ripening, bagging, custom packing and logistical management. For more information, please visit www.missionproduce.com . Forward-Looking Statements Statements in this press release that are not historical in nature are forward-looking statements that, within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, involve known and unknown risks and uncertainties. Words such as "may", "will", "expect", "intend", "plan", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "goal" and variations of these words and similar expressions, are also intended to identify forward-looking statements. The forward-looking statements in this press release address a variety of subjects, including statements about our short-term and long-term assumptions, goals and targets. Many of these assumptions relate to matters that are beyond our control and changing rapidly. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurances that our expectations will be attained. Readers are cautioned that actual results could differ materially from those implied by such forward-looking statements due to a variety of factors, including: reliance on primarily one main product; limitations regarding the supply of fruit, either through purchasing or growing; fluctuations in the market price of fruit; increasing competition; risks associated with doing business internationally, including Mexican and Peruvian economic, political and/or societal conditions; inflationary pressures; establishment of sales channels and geographic markets; loss of one or more of our largest customers; general economic conditions or downturns; supply chain failures or disruptions; disruption to the supply of reliable and cost-effective transportation; failure to recruit or retain employees, poor employee relations, and/or ineffective organizational structure; inherent farming risks, including climate change; seasonality in operating results; failures associated with information technology infrastructure, system security and cyber risks; new and changing privacy laws and our compliance with such laws; food safety events and recalls; failure to comply with laws and regulations; changes to trade policy and/or export/import laws and regulations; risks from business acquisitions, if any; lack of or failure of infrastructure; material litigation or governmental inquiries/actions; failure to maintain or protect our brand; changes in tax rates or international tax legislation; risks associated with global conflicts; inability to accurately forecast future performance; the viability of an active, liquid, and orderly market for our common stock; volatility in the trading price of our common stock; concentration of control in our executive officers, and directors over matters submitted to stockholders for approval; limited sources of capital appreciation; significant costs associated with being a public company and the allocation of significant management resources thereto; reliance on analyst reports; failure to maintain proper and effective internal control over financial reporting; restrictions on takeover attempts in our charter documents and under Delaware law; the selection of Delaware as the exclusive forum for substantially all disputes between us and our stockholders; risks related to restrictive covenants under our credit facility, which could affect our flexibility to fund ongoing operations, uses of capital and strategic initiatives, and, if we are unable to maintain compliance with such covenants, lead to significant challenges in meeting our liquidity requirements and acceleration of our debt; and other risks and factors discussed from time to time in our Annual and Quarterly Reports on Forms 10-K and 10-Q and in our other filings with the Securities and Exchange Commission. You can obtain copies of our SEC filings on the SEC’s website at www.sec.gov. The forward-looking statements contained in this press release are made as of the date hereof and the Corporation does not intend to, nor does it assume any obligation to, update or supplement any forward-looking statements after the date hereof to reflect actual results or future events or circumstances. Contacts: Investor Relations ICR Jeff Sonnek 646-277-1263 jeff.sonnek@icrinc.com Media Jenna Aguilera Marketing Communications Manager Mission Produce, Inc. press@missionproduce.com The following tables reconcile the non-GAAP measures “adjusted net income” and “adjusted EBITDA” to their comparable GAAP measures. Refer also to “Non-GAAP Financial Measures” earlier in this press release. Adjusted Net Income (1) During the three months ended October 31, 2024, $0.3 million related to blueberry orchards and $0.4 million related to avocado orchards. During the twelve months ended October 31, 2024, $2.5 million related to the blueberry orchards and $1.7 million related to avocado orchards. During the three months ended October 31, 2023, $0.5 million related to the development of blueberry orchards and $0.5 million related to avocado orchards. During the twelve months ended October 31, 2023, $2.0 million related to the development of blueberry orchards and $1.8 million related to avocado orchards. (2) Represents accelerated depreciation expense for certain blueberry plants determined to have no remaining useful life. (3) Tax effects are calculated using applicable rates that each adjustment relates to. (4) Represents net income or loss attributable to noncontrolling interest plus the impact of tax-effected non-GAAP adjustments, allocable to the noncontrolling owner based on their percentage of ownership interest. Adjusted EBITDA (1) Includes interest expense from finance leases, the most significant of which is for nonproductive land at our Blueberries segment of $0.3 million and $0.4 million for the three months ended October 31, 2024 and 2023, respectively, and $1.8 million and $1.4 million for the twelve months ended October 31, 2024 and 2023, respectively. (2) Includes depreciation and amortization of purchase accounting assets of $0.2 million and $0.6 million for the three months ended October 31, 2024 and 2023, respectively, and $3.7 million and $2.4 million for the twelve months ended October 31, 2024 and 2023, respectively. Includes amortization of finance leases, the most significant of which is for nonproductive land at our Blueberries segment of less than a million and $0.1 million for the three months ended October 31, 2024 and 2023, respectively, and $0.7 million and $0.6 million for the twelve months ended October 31, 2024 and 2023, respectively. The twelve months ended October 31, 2024 include $4.1 million of accelerated depreciation expense recognized during the first quarter of 2024, for certain blueberry plants determined to have no remaining useful life. (3) Represents net income (loss) attributable to noncontrolling interest plus the impact of non-GAAP adjustments, allocable to the noncontrolling owner based on their percentage of ownership interest. Segment Sales Avocado Sales Sales by TypeMcGill runs for 2TDs and North Texas becomes bowl eligible by beating Temple 24-17
NEW YORK (AP) — Los Angeles Dodgers shortstop Jose D. Hernandez was suspended for next year's Arizona Complex League season on Wednesday following a positive test for boldenone and nandrolone under baseball's minor league drug program. The 21-year-old Hernandez hit .302 with four homers and 21 RBIs in 26 games this year for the ACL Dodgers. The Venezuelan agreed to a contract with the Dodgers in 2019 that included a $10,000 signing bonus. Twenty players have been suspended this year for positive drug tests, including nine under the minor league program and nine under the new program for minor league players assigned outside the United States and Canada. Two players have been suspended this year under the major league drug program. Noelvi Marté , a 22-year-old infielder who was considered Cincinnati's top prospect, missed the first 80 games following a positive test for boldenone. Toronto infielder Orelvis Martínez was suspended for 80 games on June 23 following a positive test for the performance-enhancing drug clomiphene, an announcement made two days after his major league debut . ___ AP MLB: https://apnews.com/hub/mlb The Associated PressWUHAN, Nov. 30: Small plastic particles in water have become one of the most concerning consumer pollutants due to their pervasive presence in water sources. A Chinese team has developed a new strategy to remove those microplastics that adversely affect health. The study published on Saturday in the journal Science Advances described a new reusable and biodegradable foam that can absorb microplastics in water with an efficiency of up to 99.8 per cent in its first use. The researchers from Wuhan University and Huazhong University of Science and Technology employed a sustainable fibrous foam made of chitin from squid bone and cellulose from cotton. The foam has a porous structure that can attract and interact with diverse microplastics commonly found in electronics, food packaging, textiles, and other industrial products. The team evaluated the foam's performance using samples from four real-world water sources -- irrigation water, lake water, seawater and pond water -- to see if the foam would work in water found in a natural setting. The foam absorbed nearly 100 per cent of microplastics in its first cycles in samples, and the removal rates of this biopolymer-based material exceeded 95 per cent after five cycles, demonstrating its good reusability. According to the study, the material's adsorptive capacity remains basically unaffected by inorganic particles, heavy metals, organic pollutants, and microorganisms in water. "Microplastics entering terrestrial and aquatic habitats will continuously increase for thousands of years due to the alarming volumes of plastic waste in the environment," said Deng Hongbing from Wuhan University, the study's corresponding author. The study suggests that biomass materials could be a cost-effective solution for tackling the intricate problem of microplastic contamination in water, said Deng. The team has already applied for a patent for this technology, hoping to bring it into real-world water treatment or home water purifiers in the near future.Lawyer says ex-Temple basketball standout Hysier Miller met with NCAA for hours amid gambling probeRockefeller Capital Management L.P. lessened its stake in shares of Dollar General Co. ( NYSE:DG – Free Report ) by 28.0% in the third quarter, Holdings Channel.com reports. The fund owned 17,889 shares of the company’s stock after selling 6,973 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Dollar General were worth $1,532,000 at the end of the most recent reporting period. Other large investors have also modified their holdings of the company. Pzena Investment Management LLC raised its holdings in shares of Dollar General by 453.4% during the third quarter. Pzena Investment Management LLC now owns 10,238,886 shares of the company’s stock valued at $865,903,000 after acquiring an additional 8,388,735 shares during the period. Baupost Group LLC MA acquired a new stake in Dollar General during the 3rd quarter valued at $194,832,000. Point72 Asset Management L.P. lifted its holdings in shares of Dollar General by 148.6% in the second quarter. Point72 Asset Management L.P. now owns 1,280,020 shares of the company’s stock valued at $169,257,000 after purchasing an additional 765,206 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Dollar General by 319.6% in the second quarter. The Manufacturers Life Insurance Company now owns 925,083 shares of the company’s stock worth $122,324,000 after buying an additional 704,639 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Dollar General during the second quarter valued at $55,986,000. 91.77% of the stock is owned by institutional investors. Wall Street Analyst Weigh In A number of equities research analysts have commented on the company. Citigroup lowered Dollar General from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $91.00 to $73.00 in a research report on Friday, September 27th. Telsey Advisory Group decreased their price target on shares of Dollar General from $103.00 to $90.00 and set a “market perform” rating for the company in a report on Monday, December 2nd. HSBC dropped their price objective on shares of Dollar General from $100.00 to $88.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Jefferies Financial Group decreased their target price on shares of Dollar General from $110.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, Evercore ISI dropped their price target on shares of Dollar General from $97.00 to $95.00 and set an “in-line” rating on the stock in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $98.27. Insider Activity In other news, Director Warren F. Bryant purchased 1,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was purchased at an average price of $80.83 per share, with a total value of $80,830.00. Following the acquisition, the director now directly owns 42,030 shares in the company, valued at approximately $3,397,284.90. The trade was a 2.44 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link . Also, EVP Roderick J. West sold 2,510 shares of Dollar General stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.25, for a total value of $208,957.50. Following the sale, the executive vice president now directly owns 9,163 shares in the company, valued at $762,819.75. The trade was a 21.50 % decrease in their position. The disclosure for this sale can be found here . 0.49% of the stock is owned by company insiders. Dollar General Price Performance NYSE DG opened at $81.59 on Friday. Dollar General Co. has a 1 year low of $72.12 and a 1 year high of $168.07. The company has a fifty day simple moving average of $79.52 and a 200 day simple moving average of $103.60. The company has a current ratio of 1.22, a quick ratio of 0.24 and a debt-to-equity ratio of 0.86. The company has a market cap of $17.94 billion, a P/E ratio of 13.44, a P/E/G ratio of 2.33 and a beta of 0.44. Dollar General ( NYSE:DG – Get Free Report ) last released its quarterly earnings results on Thursday, December 5th. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.08). The firm had revenue of $10.18 billion for the quarter, compared to the consensus estimate of $10.14 billion. Dollar General had a net margin of 3.57% and a return on equity of 20.62%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $1.26 earnings per share. On average, sell-side analysts predict that Dollar General Co. will post 5.78 EPS for the current year. Dollar General Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 21st. Stockholders of record on Tuesday, January 7th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, January 7th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.89%. Dollar General’s dividend payout ratio (DPR) is presently 38.88%. Dollar General Profile ( Free Report ) Dollar General Corporation, a discount retailer, provides various merchandise products in the southern, southwestern, midwestern, and eastern United States. It offers consumable products, including paper and cleaning products, such as paper towels, bath tissues, paper dinnerware, trash and storage bags, disinfectants, and laundry products; packaged food comprising cereals, pasta, canned soups, fruits and vegetables, condiments, spices, sugar, and flour; and perishables that include milk, eggs, bread, refrigerated and frozen food, beer, and wine. See Also Want to see what other hedge funds are holding DG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dollar General Co. ( NYSE:DG – Free Report ). Receive News & Ratings for Dollar General Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dollar General and related companies with MarketBeat.com's FREE daily email newsletter .
Churchill Downs Incorporated (NASDAQ:CHDN) Shares Sold by Algert Global LLC
Alleged loss of lives during PTI protest: Constitutional bench declines to take suo motu notice KP AAG Shah Faisal requested bench to take suo motu notice of loss of lives during PTI protest march ISLAMABAD: The Constitutional bench on Wednesday declined to take suo motu notice of alleged loss of lives during the Pakistan Tehreek-e-Insaf (PTI) protest rally in Islamabad. A five-member Constitutional bench formed under the 26th Constitutional Amendment, headed by Justice Aminuddin Khan, heard a case related to establishment of an authority to deal with issues related to climate change. Other members of the bench included Justice Jamal Khan Mandokhail, Justice Muhammad Ali Mazhar, Justice Hassan Azhar Rizvi and Justice Musarat Hilali. During the course of hearing, KP Additional Advocate General Shah Faisal, while appearing before the bench through video link from Peshawar Registry, verbally requested the bench to take suo motu notice of loss of lives on both sides during the PTI protest march. Justice Musarat Hilali, however, asked the additional advocate general to refrain from issuing political statements before the bench. Similarly, Justice Aminuddin Khan observed that they could not address the matter which was not before them. Justice Mandokhail observed that they do not wish to comment on issues outside the court’s purview. The constitutional bench then rejected the verbal plea of KP’s additional advocate general. Meanwhile, the bench also disposed of a plea filed by founder PTI Imran Khan related to merger of Federally Administered Tribal Areas (Fata) into Khyber Pakhtunkhwa province. Babar Awan, counsel for the PTI founder chairman, submitted before the court that as the matter has already been finalised by the Khyber Pukhtunkhwa Assembly, hence no further judicial action was necessary on the petition.
Michkov scores in OT to give Flyers 3-2 victory over BluesTenon Financial LLC trimmed its holdings in shares of Amazon.com, Inc. ( NASDAQ:AMZN – Free Report ) by 2.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,465 shares of the e-commerce giant’s stock after selling 133 shares during the quarter. Amazon.com accounts for about 0.6% of Tenon Financial LLC’s portfolio, making the stock its 17th largest position. Tenon Financial LLC’s holdings in Amazon.com were worth $832,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMZN. PayPay Securities Corp lifted its position in Amazon.com by 64.6% during the 2nd quarter. PayPay Securities Corp now owns 163 shares of the e-commerce giant’s stock worth $32,000 after acquiring an additional 64 shares during the period. Hoese & Co LLP acquired a new stake in Amazon.com during the 3rd quarter worth about $37,000. Bull Oak Capital LLC acquired a new stake in Amazon.com during the 3rd quarter worth about $45,000. Christopher J. Hasenberg Inc lifted its position in Amazon.com by 650.0% during the 2nd quarter. Christopher J. Hasenberg Inc now owns 300 shares of the e-commerce giant’s stock worth $58,000 after acquiring an additional 260 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in Amazon.com during the 3rd quarter worth about $56,000. 72.20% of the stock is currently owned by hedge funds and other institutional investors. Insider Activity at Amazon.com In other Amazon.com news, SVP David Zapolsky sold 2,190 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $195.00, for a total transaction of $427,050.00. Following the transaction, the senior vice president now owns 62,420 shares of the company’s stock, valued at approximately $12,171,900. This trade represents a 3.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, Director Jonathan Rubinstein sold 4,766 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $209.85, for a total value of $1,000,145.10. Following the transaction, the director now directly owns 94,630 shares in the company, valued at approximately $19,858,105.50. The trade was a 4.79 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 6,026,683 shares of company stock valued at $1,252,148,795 over the last quarter. 10.80% of the stock is owned by insiders. Analyst Upgrades and Downgrades Read Our Latest Stock Analysis on AMZN Amazon.com Stock Up 1.0 % Shares of NASDAQ AMZN opened at $207.89 on Friday. The stock has a market cap of $2.19 trillion, a P/E ratio of 44.52, a PEG ratio of 1.38 and a beta of 1.14. The company has a current ratio of 1.09, a quick ratio of 0.87 and a debt-to-equity ratio of 0.21. Amazon.com, Inc. has a 12-month low of $142.81 and a 12-month high of $215.90. The business’s fifty day simple moving average is $194.78 and its 200-day simple moving average is $186.94. Amazon.com ( NASDAQ:AMZN – Get Free Report ) last posted its earnings results on Thursday, October 31st. The e-commerce giant reported $1.43 EPS for the quarter, beating the consensus estimate of $1.14 by $0.29. The firm had revenue of $158.88 billion for the quarter, compared to analyst estimates of $157.28 billion. Amazon.com had a return on equity of 22.41% and a net margin of 8.04%. Amazon.com’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.85 earnings per share. As a group, equities analysts predict that Amazon.com, Inc. will post 5.29 EPS for the current fiscal year. Amazon.com Profile ( Free Report ) Amazon.com, Inc engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. See Also Five stocks we like better than Amazon.com 3 Monster Growth Stocks to Buy Now The Latest 13F Filings Are In: See Where Big Money Is Flowing What is a SEC Filing? 3 Penny Stocks Ready to Break Out in 2025 Find and Profitably Trade Stocks at 52-Week Lows FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential Receive News & Ratings for Amazon.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amazon.com and related companies with MarketBeat.com's FREE daily email newsletter .None
AP News Summary at 11:51 a.m. ESTNone